Table 1.

Summary of studies showing the extent of EPCs incorporation to the tumor vasculature

EPC incorporation (%)	Type of tumor	BM donor	Markers used	Reference
<0.01	B16 melanoma	VEGFR-2/Lac-Z	Lac-Z, CD31, CD105,    von Willebrand factor	[14]
<0.01		GFP	GFP, CD31	[17]
80–100	B6RV2 lymphoma	Lac-Z	Von Willebrand factor, Lac-Z	[6]
<0.01		End-SCL-Cre-ERt	Lac-Z, CD31	[13]
<0.01	Lewis lung carcinoma	End-SCL-Cre-ERt	Lac-Z, CD31	[13]
<0.01		GFP	GFP, CD31	[17]
0.01–0.15		GFP	GFP, CD31	[24]
0.02		Tie-2/GFP	GFP, CD31	[12]
1–2		GFP	Lin−c-kit+Sca-1+, GFP, CD31	[15]
50–100		Lac-Z	Von Willebrand factor, Lac-Z	[6]
50	MCA/129 fibrosarcoma	Lac-Z	Von Willebrand factor, Lac-Z	[11]
7–10	MMTV-PyMT spontaneous    mammary carcinoma	GFP	CD31, VE-cadherin, GFP	[5]
2.5–3.5	MT1A2 mouse mammary    carcinoma	Tie2/Lac-Z	Lac-Z, CD31	[17]
7–10	Namalwa lymphoma	Human BM	Human CD31, CD34, CD133	[74]
10–25	Spontaneous tumor    (NOD/SCID/β-    glucuronidase −/−)	NOD/SCID/β-glucuronidase	β-Glucuronidase, VE-cadherin	[29]
0.5	TG1-1 mouse mammary    carcinoma	GFP	GFP, CD133	[75]
<0.01		GFP	GFP, CD31	[17]

The selected studies all used bone marrow transplantation followed at least 4 weeks later by tumor implantation. Models of parabiosis or ex vivo injection of EPCs were not included